Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series

Mayo Clinic Proceedings

Volumn 92, Issue 11, 2017, Pages 1617-1624

  Hefazi, Mehrdad ^a   Patnaik, Mrinal M ^a   Hogan, William J ^a   Litzow, Mark R ^a   Pardi, Darrell S ^a   Khanna, Sahil ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FIDAXOMICIN; METRONIDAZOLE; PREDNISONE; VANCOMYCIN; VINBLASTINE; VINCRISTINE; CYTOTOXIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HEART ARREST; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MALE; RECURRENT INFECTION; RETROSPECTIVE STUDY; SAFETY; SOLID MALIGNANT NEOPLASM; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT DURATION; COMPLICATION; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PSEUDOMEMBRANOUS COLITIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CYTOTOXINS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85037677159     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2017.08.016     Document Type: Article

References (23)

1. Magill, S.S., Edwards, J.R., Bamberg, W., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:13 (2014), 1198–1208.
2. Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:9 (2015), 825–834.
3. Gorschlüter, M., Glasmacher, A., Hahn, C., et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:6 (2001), 786–791.
4. Neemann, K., Freifeld, A., Clostridium difficile-associated diarrhea in the oncology patient. J Oncol Pract 13:1 (2017), 25–30.
5. Anand, A., Glatt, A.E., Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17:1 (1993), 109–113.
6. Kelly, C.P., LaMont, J.T., Clostridium difficile: more difficult than ever. N Engl J Med 359:18 (2008), 1932–1940.
7. Hu, M.Y., Katchar, K., Kyne, L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136:4 (2009), 1206–1214.
8. Cornely, O.A., Miller, M.A., Fantin, B., Mullane, K., Kean, Y., Gorbach, S., Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:19 (2013), 2493–2499.
9. Chung, M.S., Kim, J., Kang, J.O., Pai, H., Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 35:11 (2016), 1771–1776.
10. Gough, E., Shaikh, H., Manges, A.R., Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:10 (2011), 994–1002.
11. Cammarota, G., Masucci, L., Ianiro, G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41:9 (2015), 835–843.
12. Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:7 (2014), 1065–1071.
13. Rubin, T.A., Gessert, C.E., Aas, J., Bakken, J.S., Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 19 (2013), 22–26.
14. Webb, B.J., Brunner, A., Ford, C.D., Gazdik, M.A., Petersen, F.B., Hoda, D., Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 18:4 (2016), 628–633.
15. Patel, N.C., Griesbach, C.L., DiBaise, J.K., Orenstein, R., Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience. Mayo Clin Proc 88:8 (2013), 799–805.
16. Tariq, R., Weatherly, R., Kammer, P., Pardi, D.S., Khanna, S., Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection. [published online December 14, 2016] J Clin Gastroenterol, 0(0), 2016, 1, 10.1016/j.mayocp.2017.08.016.
17. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:4 (2013), 478–498.
18. Brandt, L.J., Aroniadis, O.C., Mellow, M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107:7 (2012), 1079–1087.
19. Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9:12 (2011), 1044–1049.
20. Mandalia, A., Ward, A., Tauxe, W., Kraft, C.S., Dhere, T., Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile. Int J Colorectal Dis 31:5 (2016), 1059–1060.
21. Mackall, C.L., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 18:1 (2000), 10–18.
22. Parmar, S.R., Bhatt, V., Yang, J., Zhang, Q., Schuster, M., A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract 20:3 (2014), 172–182.
23. Di Bella, S., Gouliouris, T., Petrosillo, N., Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother 21:4 (2015), 230–237.